Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Evista (Raloxifene) – US: CAFC affirms extension of 30-month stay against Teva’s generic Evista: Eli Lilly & Co v Teva Pharmas. USA, Inc (Orange Book Blog) (FDA Law Blog) (Patent Baristas) (Law360) (Patent Docs) (Patent Prospector) (Patently-O) (GenericsWeb) (Hal Wegner)

Cipramil (Citalopram) – UK: House of Lords upholds second-generation patent that had been invalidated at first instance for insufficiency: Generics (UK) Limited and others v H Lundbeck A/S (Managing Intellectual Property)(IPKat)

US: Congressman Waxman tells GPhA meeting that Hatch-Waxman model will work for follow-on biologics; draws praise from Coalition for a Competitive Pharmaceutical Market (Patent Docs) (GenericsWeb)

Enforcement, creative R&D financing priority issues for public health in 2009 (Intellectual Property Watch)

Industry pushes for biosimilars approval process; some IGOs take notice (Intellectual Property Watch)

International health groups warn WHO, WTO on medicines seizures (Intellectual Property Watch)

Will GSK break the Doha impasse in the global drug pricing crisis? (Patent Docs) (Afro-IP)

Access to drugs: Gilead’s non exclusive model (Afro-IP) (GenericsWeb)

India: Drug patent linkage is subject of court case, dispute in India (Intellectual Property Watch)

India: Ranbaxy’s manufacturing woes deepen; USFDA invokes Application Integrity Policy against Paonta Sahib facility (FDA Law Blog)

UK patent practice on human embryos post-WARF (IPKat)

US: Congressman Waxman tells GPhA meeting that Hatch-Waxman model will work for follow-on biologics; draws praise from Coalition for a Competitive Pharmaceutical Market (Patent Docs) (GenericsWeb)

US: Will this be the year for generic biologics? Under what terms? (Patent Baristas)

US: Teva releases second video in year of affordable healthcare campaign (SmartBrief)

US: Discussion of NYT article ‘Crop Scientists Say Biotechnology Seed Companies are Thwarting Research’ (Patent Docs) (Patent Baristas)

US FDA: Genetically engineered organisms can be patented (RelatIP)

US: Kabushiki Kaisha Hayashibara Seibutsu Kaguku Kenkyujo seeks review and correction of patent term adjustment for patent covering ‘embolic materials’ (Patent Docs)

US: Phylonix Pharmaceuticals files patent infringement suit against Zygogen over its manufacture and sale of Z-Tag Angiogenesis Assay and related compound screening services (Patent Docs)

US: Intema files patent infringement suit over Perkin Elmer’s marketing of Modified Sequential Screening protocol: Intema Ltd v NTD Laboratories, Inc et al (Patent Docs)

US: District Court Delaware: Motion to dismiss claims plaintiff not patent owner based on incorrect admission in unrelated case: Genetics Institute, LLC v. Novartis Vaccines and Diagnostics, Inc (Property, intangible)

US CAFC reopens DNA detection patent case between Enzo Biochem and former Applera (Law360)

US District Court E D California: Antitrust and patent misuse claims tossed in case alleging California Table Grape Commission accepted royalties from growers for invalid patents covering grape varieties (Law360)

US: AntiCancer launches second effort to convince federal court that Cambridge Research & Instrumentation infringed three patents covering use of fluorescent proteins to track cancer growth (Law360)

Adderall (Dextroampthetamine/Levoamphetamine) – US: CAFC agrees to hear interlocutory appeal of Shire’s patent infringement case against Sandoz over Adderall that raises question of whether patentee is precluded from relitigating claim construction issues determined in previous case (Law360)

Cancidas (Caspofungin) – Denmark: First paediatric extension application filed in Denmark, for Merck & Co’s Cancidas (The SPC Blog)

Cipramil (Citalopram) – UK: House of Lords upholds second-generation patent that had been invalidated at first instance for insufficiency: Generics (UK) Limited and others v H Lundbeck A/S (Managing Intellectual Property)(IPKat)

Crestor (Rosuvastatin) – US: Federal judge keeps Aurobindo Pharma in multidistrict patent litigation over AstraZeneca’s Crestor despite lack of subject matter jurisdiction objections (Law360)

Ethyol (Amifostine) – US: MedImmune sues Sun and Caraco again for alleged infringement of two patents relating to Ethyol (Law360)

Evista (Raloxifene) – US: CAFC affirms extension of 30-month stay against Teva’s generic Evista: Eli Lilly & Co v Teva Pharmas. USA, Inc (Orange Book Blog) (FDA Law Blog) (Patent Baristas) (Law360) (Patent Docs) (Patent Prospector) (Patently-O) (GenericsWeb) (Hal Wegner)

Famvir (Famciclovir) – US: Teva loses bid to toss Novartis wilful infringement claims over Famvir (Law360)

Fentora (Fentanyl) – US: Barr alleges Cima and Cephalon’s patent suit just a delay tactic (Law360)

Integrilin (Eptifibatide) – US: Schering alleges patent infringement following Teva’s Para IV certification as part of ANDA for generic Integrilin: Millennium Pharmaceuticals Inc. et al. v. Teva Parenteral Medicines Inc. et al. (Patent Docs)

Lexapro (Escitalopram) – US: Supreme Court refuses to hear appeal from Forest Lab’s allowing Caraco to continue bid to invalidate Lexapro patent despite Forest’s earlier covenant to sue (Law360) (Hal Wegner)

Lotrel (Amlodipine) – US: Par and Novartis settle Lotrel lawsuit (Patent Docs) (GenericsWeb)

Lovenox (Enoxaparin) – US: Amphastar antitrust claims nixed in Lovenox suit against Sanofi-Aventis (Law360)

Opana (Oxymorphone) – US: Endo Pharma, Penwest Pharma settle litigation with Activis over generic Opana (GenericsWeb)

Prandin (Repaglinide) – US: Novo Nordisk seeks to halt Caraco launch of generic Prandin (Law360)

Seroquel (Quetiapine) – US: AstraZeneca files patent infringement suit following Para IV certification as part of Accord’s filing of amended ANDA to manufacture generic Seroquel (Patent Docs)

Skelaxin (Metaxalone) – US: King Pharmaceuticals’ patents on Skelaxin invalidated by District Court E D New York (Patent Docs)

Synagis (Palivizumab) – US: PTO gives thumbs up to Genentech’s Cabilly patent (Patent Baristas)

TriCor (Fenofibrate) – US: Federal judge refuses to dismiss bulk of claims in patent, antitrust suit brought by Ethypharm against Abbott Lab’s

Tykerb (Lapatinib) – India: Cipla files post-grant opposition for Glaxo’s Lapatinib patent (Patent Circle)

Visudyne(Verteporfin) – US: CAFC refuses to rehear appeal of ruling holding QLT liable for unfair trade practices, unjust enrichment in patent ownership dispute with Harvard Medical School affiliate (Law360)

Zymar (Gatifloxacin) – US: Apotex argues Allergan’s Zymar patent invalid for inequitable conduct (Law360)